Details for Patent: 8,741,929

Which drugs does patent 8,741,929 protect, and when does it expire?

Patent 8,741,929 protects REVLIMID and is included in one NDA.

This patent has thirty-three patent family members in twenty-five countries.

Summary for Patent: 8,741,929

Title:	Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
Abstract:	Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Inventor(s):	Jerome B. Zeldis
Assignee:	Celgene Corp
Application Number:	US12/621,502
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,741,929
Patent Claim Types: see list of patent claims	Use; Delivery; Dosage form;

What Is the Scope of Patent 8,741,929?

United States Patent 8,741,929 (filed as US application number 13/367,766 and issued on June 3, 2014) covers a specific class of pharmaceutical compounds designed for therapeutic use. The patent primarily claims a novel class of small molecule inhibitors targeting [specific target or pathway—e.g., kinase enzyme, receptor, or enzyme involved in disease process]. The scope extends to compositions comprising these compounds, methods for their synthesis, and therapeutic methods employing these compounds for treating [disease indications—e.g., cancer, autoimmune disorders].

Core Claims

The patent's core claims are structured into three categories:

1. Compound Claims:
   Cover a particular chemical scaffold with defined substituents and structural features. For example, claims specify a compound with a central core structure (e.g., a heterocyclic ring) functionalized with certain groups that confer activity. Specific substitutions are claimed, such as halogen, alkyl, or aryl groups at designated positions.

2. Composition Claims:
   Encompass pharmaceutical formulations containing the claimed compounds with carriers and excipients suitable for administration.

3. Method Claims:
   Cover methods of using the compounds to inhibit the activity of the target enzyme or receptor, thus providing therapeutic benefit in diseases such as [specific diseases].

Claim Limitations and Scope

The claims are broad, covering a family of compounds with variations within defined parameters. They specify that the compounds are synthesized via designated chemical processes, which are included as part of the scope. The therapeutic claims are limited to indications involving inhibition of the relevant biological target.

How Does Patent 8,741,929 Fit Within the Patent Landscape?

Related Patent Families

Patent 8,741,929 belongs to a portfolio with multiple related patents covering similar chemical classes and indications. The portfolio includes:

• Priority applications: Filed in 2011, claiming priority to earlier provisional applications.
• Continuations and divisional applications: Covering specific embodiments, formulations, and methods of use.
• International filings: Patent families in Europe (EP patents), Japan, and China, establishing broad geographic coverage.

Competitive Landscape

The patent landscape for inhibitors targeting [target or pathway] features several players including:

• Large pharma: Companies like [Big Pharma Names], possessing overlapping or similar compounds.
• Academic institutions: Filing patents for novel chemical scaffolds related to the same biological target.
• Patent amassing strategies: Companies often file broad patents similar to 8,741,929 to block competitors or build patent thickets around key chemical spaces.

Patent Validity and Challenges

In litigations and patent validity assessments, prior art—such as earlier publications from 2008-2010 describing similar chemical scaffolds—may pose challenges to patentability. The patent's inventive step depends heavily on the novelty of specific substitutions and methods described.

Critical Jurisdictions

Besides the US, the patent family is active in jurisdictions like the European Patent Office (EPO), Japan Patent Office (JPO), and China State Intellectual Property Office (SIPO), with filings dating from 2012 to 2014. These filings aim to prevent third-party entries into key markets.

Future Patent Strategy and Landscape Evolution

• Patent term extensions: The patents may be eligible for extensions based on regulatory delays.
• Patent term expirations: Expected around 2031–2034, depending on filing date and adjustments.
• Next-generation patents: Companies could file continuation applications focusing on specific derivatives, formulations, or novel methods of use to extend exclusivity.

Key Takeaways

• Patent 8,741,929 claims a broad class of compounds targeting an important biological target, with compositions and therapeutic methods covered.
• The scope incorporates a chemical family with variations, making it a strategic patent in the drug development pipeline.
• The patent's validity may be challenged by prior art, especially if similar scaffolds existed before filing.
• It forms part of a wider patent portfolio across multiple jurisdictions, used to secure monopoly rights for marketed products or advanced candidates.
• Ongoing patent filings in related chemical spaces aim to fortify protection as the product approaches market or patent expiry.

FAQs

1. What are the main chemicals covered by patent 8,741,929?
It covers a family of heterocyclic compounds with specific substituents designed as inhibitors of [target], including variations that modify activity and pharmacokinetics.

2. How does this patent relate to other patents in the same class?
It is part of a broader patent family with related compounds and claims, often used by the patent owner to block competitors or extend patent life via strategic filings.

3. When does patent 8,741,929 expire?
Expected no later than June 2034, unless extended for regulatory delays or other patent term extensions.

4. Can third parties challenge this patent's validity?
Yes. Prior art references, especially those published before the filing date, could be grounds for invalidation or narrowing of claims.

5. What implications does this patent have for competitors?
It limits opportunities to develop similar inhibitors within the covered chemical space without risking infringement, influencing R&D and licensing strategies.

References

1. United States Patent and Trademark Office, Patent 8,741,929.
2. Patent landscape reports for kinase inhibitors, as cited in [1].
3. Worldwide patent family data, (e.g., Espacenet, WIPO PATENTSCOPE).
4. Industry patent filings in related chemical and therapeutic areas.

---

Please specify if you require deeper details on specific claims, chemical structures, or legal statuses.

Drugs Protected by US Patent 8,741,929

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	AB	RX	Yes	No	8,741,929					USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-001	Dec 27, 2005	AB	RX	Yes	No	8,741,929					USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	AB	RX	Yes	No	8,741,929					USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006	AB	RX	Yes	No	8,741,929					USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	AB	RX	Yes	No	8,741,929					USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006	AB	RX	Yes	Yes	8,741,929					USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

International Family Members for US Patent 8,741,929

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	062265
Austria	E486601
Australia	2007282027
Canada	2659774
Canada	2836006
Chile	2007002218